Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development

Summary

Halozyme and Incyte have signed a collaboration agreement to develop INCA033989 as a subcutaneous formulation using Halozyme's ENHANZE technology. This partnership combines Halozyme's drug delivery platform with Incyte's therapeutic program.